International Journal of Oncology Special Issues

CAR T cell therapy - quo vadis

Lead Editor:

    Professor Michael Schmitt
    Heidelberg University Hospital
    Germany

CAR T cells have become a very powerful instrument in the armamentarium against CD19+ lymphoma and leukemia, as well as against BCMA+ multiple myeloma. This issue will update clinician with novel targets, CAR constructs and novel analysis of parameters for clinical responses to CAR T cell theray. Moreover, gene expression profiling of both malignant cells and CAR T cells can help us towards a better understanding of the success and failure in CAR T cell therapy.


Submission deadline: 22 July 2022

Diagnostic and molecular targeting INSM1-associated signaling axis in neuroendocrine tumors

Lead Editor:

    Professor Michael Lan
    LSUHSC
    United States

Insulinoma-associated-1 (IA-1 or INSM1) cDNA encodes a zinc-finger transcription factor, which was isolated from a human insulinoma subtraction library, with specific expression patterns, predominantly in developing neuroendocrine (NE) tissues and tumors. INSM1 functions as a key differentiation factor in early pancreatic endocrine, sympatho-adrenal lineage, and pan-neurogenic precursor development. Deletion of INSM1 gene expression results in impairment of pancreatic beta-cells, catecholamine biosynthesis, and basal progenitor development during mammalian neocortex maturation. Recent studies revealed that elevated INSM1 expression in NE tumors (NETs) signifies that INSM1 is a superior biomarker for diagnostic and molecular target in NETs. NETs are tumors from cells that release hormones into the blood in response to a signaling from the nervous system. More than a dozen of NETs include carcinoid tumors, islet cell tumors, medullary thyroid cancer, pheochromocytomas, NE carcinoma of the skin (Merkel cell cancer), pulmonary NE tumors (small cell lung cancer, large cell NE carcinoma, and lung carcinoid), pituitary tumor, parathyroid carcinoma, gastroentero-pancreatic NE tumors, medulloblastoma, neuroblastoma, retinoblastoma, and genitourinary tract tumors (NE tumor of the cervix, prostate). Although they share similar NE features, it is known that distinct pathogenesis and oncogenic pathways are involved in each individual cancer. Therefore, it is feasible to target INSM1 biomarker and its associated signaling axis as a novel therapeutic approach for new options in NET treatment.


Submission deadline: 19 July 2022

Molecular Targets of Metastatic Cancers, the Biological, Clinical and Therapeutic Perspectives

Lead Editor:

    Professor Wen g Jiang
    Cardiff University School of Medicine
    United Kingdom

This special issue is devoted to studies on molecular targets of metastatic cancers and aims to report findings of those targets that contribute to metastasis of cancers. Studies conducted at molecular, cellular, clinical and therapeutic levels to discover the molecular and cellular mechanisms, clinical and therapeutic implications of the targets in cancers and metastatic cancers are welcome. Quality original research articles and reviews are considered.


Submission deadline: 13 July 2022

Journal Cover

Cover Legend PDF

June-2022
Volume 60 Issue 6

Print ISSN: 1019-6439
Online ISSN: 1791-2423

Sign up for eToc alerts

Recommend to Library

Full Size Image